FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to internal diseases, and is intended for prevention and/or treatment of hyperphosphatemia and dyslipidemia caused by renal insufficiency. To prevent and/or treat the increase of lipoprotein (a) (Lp(a)) levels in blood serum caused by renal insufficiency, a pharmaceutical preparation containing a pharmaceutically effective amount of nicotinamide is used. For preventing and/or treating high blood serum phosphate (hyperphosphatemia) and increasing blood serum lipoprotein (a) (Lp(a)) levels, wherein both disorders are caused by renal insufficiency, using a pharmaceutical preparation containing a pharmaceutically effective amount of nicotinamide.
EFFECT: using the group of inventions provides effective prevention and/or treatment of hyperphosphatemia and dyslipidemia caused by renal insufficiency.
24 cl, 8 dwg, 8 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FEED SUPPLEMENT IN TABLET FORM FOR CATS WITH CHRONIC KIDNEY INSUFFICIENCY | 2022 |
|
RU2802063C1 |
| USE OF DERIVATIVES CONTAINING THE C-O-P BONDS IN THE PATIENTS WITH RENAL INSUFFICIENCY | 2014 |
|
RU2725626C2 |
| NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | 2014 |
|
RU2675364C2 |
| NHE3 BINDING COMPOUNDS AND METHODS FOR PHOSPHATE TRANSPORT INHIBITION | 2014 |
|
RU2786149C2 |
| PHOSPHATE ADSORBENT | 2010 |
|
RU2527682C2 |
| USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM | 2013 |
|
RU2666995C2 |
| THERAPEUTIC AGENTS FOR REGULATING SERUM PHOSPHORUS LEVEL | 2012 |
|
RU2612912C2 |
| AGENT FOR LOW-TURNOVER METABOLIC BONE DISEASE IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY | 2012 |
|
RU2491940C1 |
| ORAL COMPOSITION FOR PHOSPHOROUS COMPOUNDS ABSORPTION | 2005 |
|
RU2392926C2 |
| ARYLFLUOROPHOSPHATE INHIBITORS OF INTESTINAL APICAL MEMBRANE SODIUM/PHOSPHATE CO-TRANSPORT | 2011 |
|
RU2566757C2 |
